Skip to main content
OpenTrials
Completed

NCT Number: NCT04805177

Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage

The aim of this pilot study is to provide an assessment of safety and feasibility of early minimally invasive image guided endoscopic hematoma evacuation (within 24 hours of symptom onset) in patients suffering from intracerebral haemorrhage (ICH).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Neurology, University Hospital Basel, Basel, Switzerland

Loading trial locations.

About this study

Spontaneous supratentorial intracerebral haemorrhage (SSICH) is the is the second most common form of stroke. The aim of this single centre, single arm pilot study is to provide an assessment of safety and feasibility of early minimally invasive image guided endoscopic hematoma evacuation (within 24 hours of symptom onset) in patients suffering from intracerebral haemorrhage (ICH).

Furthermore this study contributes to the understanding of secondary neuronal damage involved in ICH through the measurement of biomarkers for neuronal damage and their response to early hematoma evacuation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No relevant disability prior to ICH (mRS 0-1 prior to ICH)
  • Primary supratentorial deep or superficial intraparenchymal ICH of volume ≥ 20 mL < 100 mL (measured using formula) demonstrated on CT or MRI, with or without a 2 component of intraventricular haemorrhage
  • CT/MRI demonstrates ICH stability (< 5 mL growth) at 6 hours after the admission scan if surgery is performed >6 hours after admission CT
  • NIHSS ≥ 8 OR if a patient with a NIHSS<8 presents with at least one of the following deficits:
  • a severe hemiparesis (4 motor points on the NIHSS for facial palsy, motoric upper and lower extremities combined); OR
  • a severe motor or sensory aphasia (2 points on the NIHSS); OR
  • a profound hemi-inattention (formerly neglect, 2 points on the NIHSS); OR
  • a decreased level of consciousness (GCS<13)
  • Presenting GCS 5 - 15
  • Endoscopic haematoma evacuation can be initiated within 24 hours of symptom onset
  • Systolic blood pressure can be controlled at <160 mmHg

Exclusion criteria

  • Imaging:
  • "Spot sign" identified on CT angiography (CTA)
  • Structural vascular or brain lesion as suspected cause of ICH, such as a vascular malformation (cavernous malformation, arteriovenous malformation (AVM) etc), aneurysm, neoplasm
  • Haemorrhagic conversion of an underlying ischemic stroke
  • Infratentorial haemorrhage
  • Large associated intra-ventricular haemorrhage requiring treatment for related mass effect or shift due to trapped ventricle (extraventricular drainage (EVD) for intracranial pressure (ICP) management is allowed)
  • Midbrain extension/involvement
  • Coagulation Issues:
  • Oral or parenteral therapeutic anticoagulation which cannot be pharmacologically reverted until the planned time of evacuation
  • Known hereditary or acquired haemorrhagic diathesis, coagulation factor deficiency
  • Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction
  • international normalized ratio (INR) > 1.5 for any reason, elevated prothrombin time or activated partial thromboplastin time (aPTT), which cannot be corrected or otherwise accounted for (i.e., lupus anti-coagulant)
  • Presenting GCS 3 or 4
  • Requirement for emergent surgical decompression or uncontrolled ICP after EVD
  • Unable to obtain consent from patient or appropriate surrogate (for patients without competence)
  • Pregnancy, breast-feeding, or positive pregnancy test [either serum or urine] (woman of child-bearing potential must have a negative history of current pregnancy prior to the study procedure)
  • Evidence of active infection (indicated by fever ≥38°C) at the time of study inclusion
  • Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days
  • Based on physician's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule
  • Active drug or alcohol use or dependence

Treatment and study plan

hematoma evacuation

Procedure

early minimally invasive image guided hematoma evacuation in patients suffering from ICH

Primary outcomes

  1. Level of disability

    Time frame: 6 month after treatment onset

    level of disability 6 months after treatment, measured by the modified Rankin Scale (mRS). Good functional outcome is defined by a score on the mRS of ≤3.

  2. Change in hematoma volume to ≤15 mL

    Time frame: from baseline to 24 hours after treatment

    Change in hematoma volume to ≤15 mL

  3. number of specific adverse events (AE)

    Time frame: 6 month after treatment onset

    number of specific adverse events (AE) (death, ischemic stroke, recurrent ICH (defined as any increase in hematoma volume at follow-up that is associated with a worsening of the focal-neurological deficit by ≥4 points on the National Institute of Health Stroke Scale (NIHSS) and/or a decrease in consciousness by ≥2 points on the Glasgow Coma Scale (GCS), epileptic seizure, infection, any need for open neurosurgical procedures)

Secondary outcomes

  1. Change in relative (percentage) hematoma volume

    Time frame: from baseline to 24 hours after treatment

    Change in relative (percentage) hematoma volume

  2. Change of focal neurological deficit measured by the NIHSS

    Time frame: from baseline to 6 months

    Change of focal neurological deficit measured by the NIHSS. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.

  3. Change of serum biomarkers of brain injury

    Time frame: from baseline to 6 months

    Change of serum biomarkers of brain injury (light-chain neurofilament subunit (NfL), the Glial Fibrillary Acidic Protein (GFAP) and the S100 calcium-binding protein B (S100B))

  4. Total time spent on the intensive care unit

    Time frame: from baseline to hospital discharge (approx. 1 month)

    Total time spent on the intensive care unit

  5. Total time spent in intubation

    Time frame: from baseline to hospital discharge (approx. 1 month)

    Total time spent in intubation

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Collaborators

  • Swiss Heart Foundation

Registry information

Official study title

Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage: a Prospective Pilot Study

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Mar 18, 2021
Registry last updated
Aug 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.